SCHEMBL29327959

SCHEMBL29327959

CCc1ccc(-c2nc3cc(NC(=O)c4nc(C#N)ccc4S(C)(=O)=O)cc(Cl)c3o2)cc1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 8/20 0.49
▸ CYP2C8 P10632 1/20 0.42
▸ MAPT P10636 6/20 0.41
▸ TP53 P04637 4/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ CETP P11597 1/20 0.41
▸ POLB P06746 2/20 0.41
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ CASP3 P42574 1/20 0.37
▸ SENP8 Q96LD8 1/20 0.37
▸ SENP7 Q9BQF6 1/20 0.37
▸ SENP6 Q9GZR1 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29327954 0.90 MAPT (0.45) PPARGCYP2C8MAPTTP53SMN1; SMN2
SCHEMBL29327625 0.86 PPARG (0.60) PPARGCYP2C8MAPTTP53SMN1; SMN2
SCHEMBL29327984 0.86 PPARG (0.52) PPARGCYP2C8MAPTTP53SMN1; SMN2
SCHEMBL29327895 0.85 PPARG (0.64) PPARGCYP2C8MAPTTP53SMN1; SMN2
SCHEMBL29327651 0.84 PPARG (0.51) PPARGCYP2C8MAPTTP53SMN1; SMN2
SCHEMBL29327936 0.80 PPARG (0.60) PPARGCYP2C8MAPTTP53SMN1; SMN2
SCHEMBL29328005 0.79 PPARG (0.58) PPARGCYP2C8MAPTTP53SMN1; SMN2
SCHEMBL29327949 0.77 HDAC6 (0.48) PPARGMAPTTP53SMN1; SMN2NPC1
SCHEMBL29327620 0.76 TP53 (0.54) PPARGMAPTTP53SMN1; SMN2POLB
SCHEMBL29327658 0.76 PPARG (0.52) PPARGMAPTTP53POLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF PPARG, PPARA, PPARD PPARG 1/4885CYP2C8 431/4885MAPT 4591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback